Efficacy of Magnesium Sulfate in the Treatment of Bronchiolitis

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In this study, investigators will compare the efficacy and safety of intravenous (IV) Magnesium sulfate in decreasing bronchiolitis clinical severity score and the duration of hospitalization in admitted patients, as compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hamad Medical Corporation
• Treatments: Magnesium Sulfate

Criteria

Inclusion Criteria:

Infants 1-18 months of age presenting to Al Saad Pediatric Emergency Center from October 2012 to May 2015 with diagnosis of Bronchiolitis and bronchiolitis clinical severity score > 4,will be include in the study.

Exclusion Criteria:

• Prematurity (Gestational age 34 weeks or less);

• Previous history of wheezing;

• Use of steroid within 48 hours of presentation;

• CRITICALLY ill patients with one or more of the following:

1. obtunded consciousness

2. progressive respiratory failure requiring intensive care unit (PICU) admission;

3. history of apnea within 24 hours before presentation

4. oxygen saturation < 85% on room air at the time of recruitment

• History of chronic lung disease;Chronic lung disease of prematurity Cystic fibrosis;

• Congenital heart disease.

• All immunodeficient children: primary or secondary

• Known hypersensitivity to magnesium sulfate.

• Known to have magnesium or calcium metabolism disturbance. (e.g.; vitamin D deficiency, hypoparathyroidism).